Search for: "Takeda GMBH"
Results 1 - 16
of 16
Sorted by Relevance
|
Sort by Date
3 Mar 2008, 9:27 pm
Takeda Chem. [read post]
15 Sep 2009, 10:54 pm
The Takeda case [Takeda Pharmaceutical Co. v. [read post]
7 Jul 2013, 9:33 am
* Controllers decisions from January - May 2013 will be posted shortly.APPLICATION # APPLICANT Decision / Issue CONTROLLER 293/MUMNP/2008 TAKEDA GMBH Refused, 3(d) Amitava Chakraborty 5982/CHENP/2007 TECHNISCHE UNIVERSITAT DARMSTADT Refused Anoop K Joy 6063/DELNP/2006 RANBAXY LABORATORIEWS LIMITED Withdrawn - date* Ashok Kumar 4318/DELNP/2008 M/S ASTRAZECECA AB Refused, divisional ASHOK KUMAR 3724/DELNP/2006 THE UNIVERSITY OF IOWA Refused … [read post]
25 Jul 2008, 2:11 am
See Aventis Pharma Deutschland GmbH v. [read post]
1 Dec 2009, 9:45 am
(patent infringement) 11/6: Takeda Pharmaceutical Company Ltd. and Takeda Pharmaceuticals North America Inc. v. [read post]
22 Jul 2008, 7:51 pm
See Takeda Chem. [read post]
25 Oct 2008, 12:03 am
Sandoz, Inc (Law360) (Hal Wegner) (Patently-O) (Patent Prospector) (PLI) Cipro (Ciprofloxacin) - US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (IP Law Observer) Lescol (Fluvastatin) - US: Mylan confirms first-to-file patent challenge to Lescol by Novartis (SmartBrief) Levaquin (Levofloxacin) - UK: Levofloxacin SPC valid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd & Anor (IPKat) (The SPC… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
15 Sep 2010, 2:40 am
(Afro-IP) Africa: Giving consumers power in the battle against counterfeits (Afro-IP) Australia: Review Four Corners’ ‘Body Corporate’ program on gene patenting (Patentology) India: Roche and Novartis, finally, manage to defend their patents in oppositions filed by Cipla (Spicy IP) South Africa: San people push for new legislation – demand protection for indigenous knowledge and IP including medicinal remedies derived from plants including Hoodia (Afro-IP) US: PHOSITA:… [read post]
3 May 2016, 9:00 pm
Guest Post By: Paul Dietze and Mini Kapoor, Haynes and Boone, LLP[1] On March 18, 2016, the Federal Circuit held that Mylan Pharmaceuticals, Inc. [read post]
13 May 2010, 4:58 pm
(FDA Law Blog) US: Divisional of a divisional: Avoid terminal disclaimers: CAFC denies en banc rehearing in Boehringer Ingelheim International GMBH v. [read post]
7 May 2010, 11:11 am
Sulzer Morat GMBH, 139 F.3d 877, 881 (Fed. [read post]
22 Jul 2010, 8:15 pm
Wyers sued Master Lock for infringing 6,672,115, 7,165,426, and 7,225,649, applicable to hitch pin locks for trailer towing. [read post]
11 Apr 2008, 9:00 am
’ – 18 – 22 June, US/Alaska: (Public Knowledge), Center for IP 8th Annual IP Symposium – 28-30 May, Maryland US: (Public Knowledge), University of Maastricht: Conference on public health, innovation and intellectual property – 15 April, Maastricht (Netherlands): (IPR-Helpdesk), NLSIU Symposium: ‘Challenges to India’s patent regime’ – 12-13 April: (Spicy IP), Anti-counterfeiting and brand… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
